olmesartan/amlodipine/indapamide (DWJ1622)
/ Daewoong Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 06, 2025
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.
New P1 trial
December 04, 2025
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.
New P1 trial
March 19, 2025
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients with Hypertension
(clinicaltrials.gov)
- P3 | N=192 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Hypertension
1 to 3
Of
3
Go to page
1